Woodmont Investment Counsel LLC Has $12.97 Million Position in Johnson & Johnson (NYSE:JNJ)

Woodmont Investment Counsel LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 89,712 shares of the company’s stock after purchasing an additional 4,041 shares during the quarter. Johnson & Johnson comprises about 1.0% of Woodmont Investment Counsel LLC’s investment portfolio, making the stock its 25th largest position. Woodmont Investment Counsel LLC’s holdings in Johnson & Johnson were worth $12,974,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vinva Investment Management Ltd lifted its stake in shares of Johnson & Johnson by 6.8% during the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after acquiring an additional 7,110 shares during the period. Financial Counselors Inc. lifted its stake in shares of Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after acquiring an additional 9,309 shares during the period. Oregon Pacific Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $949,000. Horan Securities Inc. lifted its stake in shares of Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after acquiring an additional 90 shares during the period. Finally, Strategic Financial Concepts LLC lifted its stake in shares of Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after acquiring an additional 1,271 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company cut their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $171.33.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Up 0.2 %

NYSE:JNJ opened at $163.40 on Monday. The firm has a market capitalization of $393.76 billion, a price-to-earnings ratio of 24.57, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock’s 50 day moving average price is $156.99 and its two-hundred day moving average price is $156.17. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.29 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.